Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
- Conditions
- Multiple SclerosisFatigue
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Accelerated Cure Project for Multiple Sclerosis
- Target Recruit Count
- 2000
- Registration Number
- NCT06441617
- Locations
- 🇺🇸
Washington VA Medical Center, Washington, District of Columbia, United States
🇺🇸Portland Va Medical Center, Portland, Oregon, United States
🇺🇸Baltimore VA Medical Center, Baltimore, Maryland, United States
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Accelerated Cure Project for Multiple Sclerosis
- Target Recruit Count
- 20000
- Registration Number
- NCT02486562
- Locations
- 🇺🇸
Accelerated Cure Project, Waltham, Massachusetts, United States
Biobank For MS And Other Demyelinating Diseases
- Conditions
- Transverse MyelitisOptic NeuritisMultiple SclerosisNeuromyelitis OpticaAcute Disseminated Encephalomyelitis
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Accelerated Cure Project for Multiple Sclerosis
- Target Recruit Count
- 3226
- Registration Number
- NCT00445367
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver, Aurora, Colorado, United States
News
Octave's MSDA Test Transforms MS Care with Biomarker-Driven Insights
• Octave Bioscience's Multiple Sclerosis Disease Activity (MSDA) Test has demonstrated significant impact on clinical decision-making, influencing nearly 60% of MS management cases in a real-world study. • The multi-protein biomarker assay, which measures 18 proteins to assess MS disease activity, has received New York State CLEP certification, making it available in all 50 states. • Study findings show the MSDA Test provides objective data that supports treatment decisions, with nearly 1 in 5 test results leading clinicians to adjust MS management strategies.